![Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire](https://mms.businesswire.com/media/20220606005041/en/739014/23/teva_RGB_JPEG.jpg)
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire
![No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1631128798/AJOVY%20Image.jpg/AJOVY%20Image.jpg?VersionId=syVEFjOv7_Oy_I9QN1IbMNNg6mpwQsTc)
No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma
![Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20190401005452/en/712257/5/Ajovy_UK_Packshot_1pack-HiRes_highres.jpg)